Multidrug resistance (MDR-1) expression in aids-related lymphomas

Leukemia Research

Volumn 26, Issue 2, 2002, Pages 121-127

  Tulpule, Anil ^a,b   Sherrod, Andy ^a,b   Dharmapala, Dharshika ^a,b   Young, Lillian L ^a,b   Espina, Byron M ^a,b   Sanchez, Maria Norilyn ^a,b   Gill, Parkash S ^a,b   Levine, Alexandra M ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

AIDS NHL; Lymphoma; MDR 1

Indexed keywords

ANTIVIRUS AGENT; BLEOMYCIN; CD94 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GLYCOPROTEIN P; ISOPROTEIN; METHOTREXATE; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN; PREDNISONE; PROTEINASE INHIBITOR; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS RELATED COMPLEX; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL DIVISION; CELL STRUCTURE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLAST; IMMUNOHISTOCHEMISTRY; LEUKEMIA REMISSION; LYMPHOCYTE COUNT; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINASE INHIBITION; TUMOR BIOPSY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUCOVORIN; LYMPHOMA, AIDS-RELATED; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PREDNISONE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0036137606     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(01)00113-8     Document Type: Conference Paper

References (42)

1. Molecular mechanisms of multidrug resistance in cancer chemotherapy
2. Mechanisms of multidrug resistance and implications for therapy
3. The biochemistry of p-glycoprotein-mediated multidrug resistance
4. Biochemistry of multidrug resistance mediated by the multidrug transporter
5. The mdr1 gene, responsible for multidrug-resistance, codes for p-glycoprotein
6. Multidrug resistance
7. Identification of distinct P-glycoprotein gene sequences in rat
8. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells
9. Purification of the 170- to 180-kilodalton membrane glycoprotein associated with multidrug resistance
10. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues
11. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sties
12. Expression of a multidrug-resistance gene in human tumors and tissues
13. P-glycoprotein in adult hematologic malignancies
14. Multidrug resistance in lymphoma
15. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil
16. The prognostic relevance of glycoprotein expression in malignant lymphomas
17. Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancer
18. Expression of P-glycoprotein in B-cell non-Hodgkin's lymphoma
19. Expression of p-glycoprotein and glutathione-S-transferase in recurrent lymphomas: The possible role of Epstein-Barr virus, immunophenotypes and other predisposing factors
20. Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas
21. Acquired immunodeficiency syndrome related lymphoma
22. AIDS related malignant lymphoma: Results of prospective treatment trials
23. AIDS related lymphoid neoplasia
24. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS)
25. AIDS associated non-Hodgkin's lymphoma in San Francisco
26. Non-Hodgkin's lymphoma in a population with or at risk of acquired immunodeficiency syndrome: Indications for intensive chemotherapy
27. Low dose chemotherapy with CNS prophylaxis and Zidovudine maintenance in AIDS-related lymphoma
28. Low dose with standard dose m-BACOD chemotherapy for NHL associated with HIV infection
29. Treatment of AIDS-related non-Hodgkin's lymphoma with a twelve week chemotherapy program
30. Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma
31. HIV-related lymphoma treatment with intensive combination chemotherapy
32. Low dose m-BACOD with zalcitabine in patients with AIDS-related lymphoma
33. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastrim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma
34. Immunotoxin combined with chemotherapy for patients with AIDS-related non-Hodgkin's lymphoma
35. For the AIDS Malignancy Consortium (AMC): Chemotherapy for HIV-associated non-Hodgkin's lymphoma (HIV-NHL) in combination with highly active antiretroviral therapy (HAART) is not associated with excessive toxicity
36. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphoma
37. Report of the committee on Hodgkin's disease staging classification
38. A network algorithm for the exact treatment of Fisher's exact test in R×C contingency tables
39. On distribution-free tests for equality of survival distributions
40. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
41. HIV-1 protease inhibitors are substrates for the MDR-1 multidrug transporter